U.S., June 12 -- ClinicalTrials.gov registry received information related to the study (NCT07014930) titled 'Identification of New Tools for Predicting Natural Metabolic Performance of the Liver' on May 19.
Brief Summary: The objective of this clinical trial is to identify endogenous compounds (substances naturally present in the human body) that may serve as predictors of the activity of a key liver enzyme, CYP2C19. This enzyme plays a crucial role in the metabolism of several important drugs and exhibits significant interindividual variability in its activity, which can contribute to adverse drug reactions or reduced therapeutic efficacy.
The study will involve 40 healthy volunteers, divided into two groups: 10 poor metabolizers and 30 ...